Navigation Links
Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
Date:7/5/2012

to build a valuable organization that discovers and develops important new medications for patients."

Audet has more than 25 years of industry experience. Prior to joining Arena, he was Vice President and Head of the US Regulatory Affairs Marketed Products Group at Sanofi-Aventis from 2003 to 2008. Before this, he was the Cardiovascular Global Therapeutic Area Leader at Pfizer. He received a bachelor's degree in biology/pre-medicine from Boston College, and is in the process of obtaining his Ph.D. in Public Health.

About Arena Pharmaceuticals Arena Pharmaceuticals, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. For more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Mr. Audet's role at Arena and related expectations; the EMA's review of the lorcaserin MAA; and Arena's development, value, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing and outcome of DEA, EMA and other
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
2. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
5. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
7. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
8. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
9. Nouveau Life Pharmaceuticals (NOUV) In Talks with International Mass Distribution Firms
10. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
11. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Saxelby , its President and Chief Executive Officer, will ... and as a member of the Board of Directors, ... replaced on an interim basis by Michael T. ...
(Date:8/22/2014)... Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... begin trading on The NASDAQ Stock Market under the ...
(Date:8/21/2014)... Hermann Health System and The University of Texas ... to provide a new level of specialized breast screening at ... Houston area. Starting in ... professional breast radiology services for five of Memorial Hermann,s 10 ... Woodlands , Northeast, Southwest and Sugar Land ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 "I ... when they gave a urine sample," said an inventor ... entire process easier and mess-free, I came up with ... to allow urine samples to be collected from women ... peace of mind to patients and staff. The invention ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market ... to 2018” defines and segments the global polycarbonate ... global revenue and consumption. It also identifies driving ... market with analysis of trends, opportunities, burning issues, ... and revenues are forecasted on the basis of ...
(Date:8/23/2014)... August 23, 2014 Peripheral intervention surgeries ... remove plaques, etc, thereby addressing the root cause of ... of blood to the other part of the arteries ... blood. These procedures require the use of a catheter, ... and polymers), these catheters are inserted through a thin ...
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 Having ... inventor and dental hygienist from Arlington, Texas, saw a need ... toothbrush and toothpaste. "That’s when I came up with the ... easy-to-use No-Brush provides an effective way for a user to ... the need to carry multiple items. It also helps avoid ...
(Date:8/23/2014)... Raleigh, NC (PRWEB) August 23, 2014 A ... IMRT for mesothelioma last longer when preceded by surgery and ... an article on the new study. Click here to ... Cancer Center studied the cases of mesothelioma patients ... technique for conforming radiotherapy dose to the shape of a ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2
... Following is a,media statement attributable to Betsy ... Hospital Association:, "NJHA applauds the state upon ... This is a valuable document for New Jersey,s,hospitals ... a wealth of information on which hospitals can,focus ...
... Gaps in ... Breast Cancer Care, Survival, COLUMBUS, Ohio, Jan. 17 ... the Cure will host two events to,launch Ohio,s participation in the ... cancer care that cause some women to die,of the disease more ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) announced today ... Concept Trial" for the biopharmaceutical SF-1019 has,been successfully ... The Board of Immunosyn was advised as ... "Proof of Concept Trial" by Argyll Biotechnologies, LLC ...
... of ongoing clinical trials, expert says , , THURSDAY, Jan. 17 ... or prevent Alzheimer,s disease, a new study finds no evidence ... suggested this possibility, whether the same benefit translates to humans ... find a relation between statin use and the risk of ...
... January 18 edition (Volume 28, Issue 1) of the journal ... is known as a nonsense mutation of the Coronin-1A gene ... mutation causes the gene to produce proteins that no longer ... cytoskeleton, a network of protein fibers or filaments in the ...
... from injuries, disease , THURSDAY, Jan. 17 (HealthDay ... creating the brain,s thinking center, in a finding that ... neurodegenerative diseases. , The gene, called Lhx2, tells stem ... cortex, which controls functions such as language, decision-making and ...
Cached Medicine News:Health News:Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Latest Study Says Statins Don't Slow Alzheimer's 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 3
... HPLC system designed to provide fast and ... aid in the comprehensive identification and quantitation ... glycemic control., ,The A1c assay combines the ... accuracy of boronate affinity columns. The result ...
... fastest blood gas analyzers for ... on the market. Equally suitable ... testing. The Roche COMPACT ... reliable assessment of acid-base status ...
... sets the standard for testing blood ... at your patient's side - the ... self contained system can easily be ... ICU, or wherever you need it ...
Flatbed Agitator....
Medicine Products: